COVID-19 Conjugate Vaccine
COVID-19
Not Disclosed (Research/Preclinical)Active
Key Facts
About Inventprise
Founded in 2014 (originating from 2012), Inventprise is a private, clinical-stage biotech based in Redmond, Washington, developing novel conjugate vaccines using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker platform. Its lead candidate is a 25-valent pediatric pneumococcal conjugate vaccine (IVT PCV-25), and its pipeline includes Phase 1/2 candidates for Group B Streptococcus (GBS), Shigella, Klebsiella, and COVID-19. Led by vaccine industry veteran Dr. Subhash Kapre, the company has built state-of-the-art manufacturing capacity and grown to over 200 employees, positioning itself to address significant global infectious disease burdens.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |